Arcus Biosciences
RCUS
185 hedge funds and large institutions have $1.02B invested in Arcus Biosciences in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 68 reducing their positions, and 25 closing their positions.
100% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $7.25M
8% more capital invested
Capital invested by funds: $948M → $1.02B (+$74.9M)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
0.64% more ownership
Funds ownership: 70.89% → 71.53% (+0.64%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 68
1% less funds holding
Funds holding: 187 → 185 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.2M |
| 3 |
BlackRock
New York
|
+$6.65M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$5.76M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$6.49M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.28M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.44M |
| 5 |
Barclays
London,
United Kingdom
|
-$4.28M |
RCUS Hedge Fund Activity: Q4 2023 in Review
185 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2023, worth a combined $1.02B — up 7.9% from $948M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RCUS positions and 25 closed out — a net gain of 1 holder — while 62 added to existing stakes and 68 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.2M sold.
- 185 institutional investors held Arcus Biosciences (RCUS) as of Q4 2023, down from 187 in Q3 2023.
- Funds reported $1.02B of Arcus Biosciences stock for Q4 2023, up 7.9% quarter-over-quarter.
- 26 funds opened new Arcus Biosciences positions in Q4 2023 and 25 closed out, a net change of +1 holder.
- The largest Arcus Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.7M added.
- The largest Arcus Biosciences seller in Q4 2023 was PFM Health Sciences, an estimated $25.2M sold.
Based on aggregated 13F filings for Q4 2023.